Literature DB >> 8558068

The role of chemokines in inflammatory joint disease.

S L Kunkel1, N Lukacs, T Kasama, R M Strieter.   

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by the elicitation and activation of a number of leukocyte populations within both the synovial space and joint tissue. The recruited leukocytes subsequently play an instrumental role in synovial cell proliferation, pannus formation, and bone erosion. Although it is know that leukocytes are important participants in the evolving joint pathology, the mechanism responsible for the successful elicitation of cells to the joint is not clear. A number of studies have identified an association of specific cytokines, including chemokines, with active arthritis, but longitudinal analyses of cytokine expression and the causal role of these mediators have not been defined. Animal models and cell culture systems have proved useful in identifying the expression of various cytokines during the maintenance of chronic joint inflammation. In addition, animal models have provided important information regarding the kinetic production and contribution of specific mediators to the development of experimental arthritis. These studies provide insights into the potential mechanisms for leukocyte involvement in inflammatory joint disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558068     DOI: 10.1002/jlb.59.1.6

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  35 in total

1.  Leucocyte chemotaxis: Examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by Monocyte Chemoattractant Proteins-1, -2, -3 and -4.

Authors:  J H Wain; J A Kirby; S Ali
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

2.  Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis.

Authors:  Y Hatano; T Kasama; H Iwabuchi; R Hanaoka; H T Takeuchi; L Jing; Y Mori; K Kobayashi; M Negishi; H Ide; M Adachi
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

3.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 4.  Chemokines in rheumatoid arthritis.

Authors:  Z Szekanecz; R M Strieter; S L Kunkel; A E Koch
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Production of interleukin-6 by synovial fibroblasts in rheumatoid arthritis.

Authors:  H Baumann; I Kushner
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 6.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

7.  Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1.

Authors:  Jianru Wang; Ye Tian; Kate L E Phillips; Neil Chiverton; Gail Haddock; Rowena A Bunning; Alison K Cross; Irving M Shapiro; Christine L Le Maitre; Makarand V Risbud
Journal:  Arthritis Rheum       Date:  2013-03

Review 8.  Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention.

Authors:  Z Szekanecz; A E Koch; S L Kunkel; R M Strieter
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

9.  CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia.

Authors:  W C Tsai; R M Strieter; B Mehrad; M W Newstead; X Zeng; T J Standiford
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

10.  Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection.

Authors:  P Ø Jensen; C Moser; O Kobayashi; H P Hougen; A Kharazmi; N Høiby
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.